FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Pathogens / How to Meet the Last OIE Expert Surveillance Panel Recommend...
Pathogens (Basel, Switzerland)2016; 5(4); 64; doi: 10.3390/pathogens5040064

How to Meet the Last OIE Expert Surveillance Panel Recommendations on Equine Influenza (EI) Vaccine Composition: A Review of the Process Required for the Recombinant Canarypox-Based EI Vaccine.

Abstract: Vaccination is highly effective to prevent, control, and limit the impact of equine influenza (EI), a major respiratory disease of horses. However, EI vaccines should contain relevant equine influenza virus (EIV) strains for optimal protection. The OIE expert surveillance panel annually reviews EIV evolution and, since 2010, the use of Florida clade 1 and 2 sub-lineages representative vaccine strains is recommended. This report summarises the development process of a fully- updated recombinant canarypox-based EI vaccine in order to meet the last OIE recommendations, including the vaccine mode of action, production steps and schedule. The EI vaccine ProteqFlu contains 2 recombinant canarypox viruses expressing the haemagglutinin of the A/equine/Ohio/03 and A/equine/Richmond/1/07 isolates (Florida clade 1 and 2 sub-lineages, respectively). The updated EI vaccine was tested for efficacy against the representative Florida clade 2 EIV strain A/equine/Richmond/1/07 in the Welsh mountain pony model. Protective antibody response, clinical signs of disease and virus shedding were compared with unvaccinated control ponies. Significant protection was measured in vaccinated ponies, which supports the vaccine registration. The recombinant canarypox-based EI vaccine was the first fully updated EI vaccine available in the EU, which will help to minimise the increasing risk of vaccine breakdown due to constant EIV evolution through antigenic drift.
Get Full Text
Publication Date: 2016-11-25 PubMed ID: 27897990PubMed Central: PMC5198164DOI: 10.3390/pathogens5040064Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Review
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses the development process and effectiveness of a recombinant canarypox-based Equine Influenza (EI) vaccine, designed to be in line with the latest OIE Expert Surveillance Panel recommendations on EI vaccine composition. It outlines the steps of production, the mode of action, and the testing schedules, and concludes the vaccine was significantly protective against the representative Florida clade 2 EIV strain.

Introduction to the Research

  • The study focuses on creating an updated vaccine for Equine Influenza (EI), a major respiratory disease in horses that can be controlled effectively via vaccination.
  • In order to provide optimal protection, the EI vaccines need to contain relevant equine influenza virus (EIV) strains. The OIE expert surveillance panel reviews these strains annually, and since 2010, has recommended the use of representative vaccine strains from Florida clade 1 and 2 sub-lineages.

Vaccine Development Process

  • The researchers outline the development process for a recombinant canarypox-based EI vaccine that aligns with the latest OIE recommendations.
  • The vaccine, named ProteqFlu, contains recombinant canarypox viruses expressing haemagglutinin from the isolates A/equine/Ohio/03 and A/equine/Richmond/1/07, representative of Florida clade 1 and 2 sub-lineages respectively.
  • The process includes the steps for vaccine production and the timeline.

Vaccine Testing and Results

  • The vaccine’s effectiveness was tested against the representative Florida clade 2 EIV strain A/equine/Richmond/1/07.
  • The testing model used was the Welsh mountain pony.
  • The research team measured the protective antibody response, disease symptoms, and virus shedding, subsequently comparing them with unvaccinated control ponies.
  • The results revealed significant protective features measured in the vaccinated ponies, substantiating the grounds for vaccine registration.

Conclusions and Implications

  • This recombinant canarypox-based EI vaccine was the first fully updated EI vaccine available in the European Union.
  • Its implementation is expected to minimise the increasing risk of vaccine failure due to constant EIV evolution through antigenic drift.

Cite This Article

APA
Paillot R, Rash NL, Garrett D, Prowse-Davis L, Montesso F, Cullinane A, Lemaitre L, Thibault JC, Wittreck S, Dancer A. (2016). How to Meet the Last OIE Expert Surveillance Panel Recommendations on Equine Influenza (EI) Vaccine Composition: A Review of the Process Required for the Recombinant Canarypox-Based EI Vaccine. Pathogens, 5(4), 64. https://doi.org/10.3390/pathogens5040064

Publication

Pathogens (Basel, Switzerland)
ISSN: 2076-0817
NlmUniqueID: 101596317
Country: Switzerland
Language: English
Volume: 5
Issue: 4
PII: 64

Researcher Affiliations

Paillot, Romain
  • Animal Health Trust, Lanwades Park, Kentford Newmarket CB8 7UU, UK. romain.paillot@aht.org.uk.
Rash, Nicola L
  • Animal Health Trust, Lanwades Park, Kentford Newmarket CB8 7UU, UK. nicola.rash@aht.org.uk.
Garrett, Dion
  • Animal Health Trust, Lanwades Park, Kentford Newmarket CB8 7UU, UK. DION.GARRETT@aht.org.uk.
Prowse-Davis, Leah
  • Animal Health Trust, Lanwades Park, Kentford Newmarket CB8 7UU, UK. leah.prowse@aht.org.uk.
Montesso, Fernando
  • Animal Health Trust, Lanwades Park, Kentford Newmarket CB8 7UU, UK. fernando.montesso@aht.org.uk.
Cullinane, Ann
  • Irish Equine Centre, Johnstown, Naas, W91 RH93 Co. Kildare, Ireland. ACullinane@irishequinecentre.ie.
Lemaitre, Laurent
  • Merial SAS, 69007 Lyon, France. Laurent.LEMAITRE@merial.com.
Thibault, Jean-Christophe
  • Merial SAS, 69007 Lyon, France. Jean-christophe.THIBAULT@merial.com.
Wittreck, Sonia
  • Merial SAS, 69007 Lyon, France. Sonia.WITTRECK@Merial.com.
Dancer, Agnes
  • Merial SAS, 69007 Lyon, France. Agnes.DANCER@merial.com.

Conflict of Interest Statement

R.P., N.R., L.P.-D., D.G. and A.C. do not report any competing interest; L.L., J.-C.T., S.W. and A.D. were employed by the founding sponsor at the time of the study. The founding sponsor and authors (L.L. and A.D.) employed by the founding sponsor were involved in the design of the study but were not involved in the collection, analyses or interpretation of data. R.P., J.-C.T., L.L., S.W. and A.D. were involved in the decision to publish the results. The manuscript was reviewed by the founding sponsor prior to submission.

References

This article includes 22 references
  1. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood.. Syst Biol 2003 Oct;52(5):696-704.
    doi: 10.1080/10635150390235520pubmed: 14530136google scholar: lookup
  2. Paillot R, Kydd JH, Sindle T, Hannant D, Edlund Toulemonde C, Audonnet JC, Minke JM, Daly JM. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.. Vet Immunol Immunopathol 2006 Aug 15;112(3-4):225-33.
    doi: 10.1016/j.vetimm.2006.02.007pubmed: 16621023google scholar: lookup
  3. Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination.. Vaccines (Basel) 2014 Nov 14;2(4):797-831.
    doi: 10.3390/vaccines2040797pmc: PMC4494246pubmed: 26344892google scholar: lookup
  4. Paillot R, Hannant D, Kydd JH, Daly JM. Vaccination against equine influenza: quid novi?. Vaccine 2006 May 8;24(19):4047-61.
    doi: 10.1016/j.vaccine.2006.02.030pubmed: 16545507google scholar: lookup
  5. Guthrie AJ. Equine Influenza in South Africa 2003 Outbreak. 9th International Congress of World Equine Veterinary Association, Marrakech, Morocco, 22–26 January 2006.
  6. Paillot R, El-Hage CM. The Use of a Recombinant Canarypox-Based Equine Influenza Vaccine during the 2007 Australian Outbreak: A Systematic Review and Summary.. Pathogens 2016 Jun 10;5(2).
    doi: 10.3390/pathogens5020042pmc: PMC4931393pubmed: 27294963google scholar: lookup
  7. Kirkland PD, Delbridge G. Use of a blocking ELISA for antibodies to equine influenza virus as a test to distinguish between naturally infected and vaccinated horses: proof of concept studies.. Aust Vet J 2011 Jul;89 Suppl 1:45-6.
    doi: 10.1111/j.1751-0813.2011.00743.xpubmed: 21711288google scholar: lookup
  8. Galvin P, Gildea S, Arkins S, Walsh C, Cullinane A. The evaluation of a nucleoprotein ELISA for the detection of equine influenza antibodies and the differentiation of infected from vaccinated horses (DIVA).. Influenza Other Respir Viruses 2013 Dec;7 Suppl 4(Suppl 4):73-80.
    doi: 10.1111/irv.12195pmc: PMC5655885pubmed: 24224822google scholar: lookup
  9. European Medicines Agency Proteqflu: Epar-Scientific Discussion. [(accessed on 20 May 2016)]. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/veterinary/000073/WC500065184.pdf.
  10. European Medicines Agency. Cvmp Assessment Report for Type II Variation for Proteqflu (Emea/v/c/000073/ii/0014). European Medicines Agency; London, UK: 2014.
  11. European Medicines Agency. Cvmp Assessment Report for Type II Variation for Proteqflu te (Emea/v/c/000074/ii/0017). European Medicines Agency; London, UK: 2014.
  12. European Agency for the Evaluation of Medicinal Products. Harmonisation of Requirements for Equine Influenza Vaccines: Specific Requirements for Substitution or Addition of a Strain or Strains. Emea/Cvmp/112–98-Final. European Medicines Agency; London, UK: 1998.
  13. Gildea S, Arkins S, Walsh C, Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings--a randomised blind study.. Vaccine 2011 Nov 15;29(49):9214-23.
    doi: 10.1016/j.vaccine.2011.09.101pubmed: 21983355google scholar: lookup
  14. Paillot R, Lopez-Alvarez MR, Garrett D, Birand I, Behr-Gross M-E. Production and establishment of a new candidate horse antiserum (common oie international standard/european pharmacopoiia biological reference preparation) to the florida clade 2 equine influenza virus a/eq/richmond/1/07. J. Equine Vet. Sci. 2016;39:S72–S77.
    doi: 10.1016/j.jevs.2016.02.154google scholar: lookup
  15. . Equine Influenza Vaccine (Inactivated). European Pharmacopoeia. 7th ed. Council of Europe (European Directorate for the Quality of Medicines and Healthcare); Strasbourg, France: 2010. pp. 893–895. Monograph 0249.
  16. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.. BMJ 2010 Mar 23;340:c869.
    doi: 10.1136/bmj.c869pmc: PMC2844943pubmed: 20332511google scholar: lookup
  17. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.. PLoS Med 2010 Mar 24;7(3):e1000251.
    doi: 10.1371/journal.pmed.1000251pmc: PMC2844794pubmed: 20352064google scholar: lookup
  18. Paillot R, Grimmett H, Elton D, Daly JM. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host.. Vet Res 2008 May-Jun;39(3):21.
    doi: 10.1051/vetres:2007062pubmed: 18252187google scholar: lookup
  19. Reed LJ, Muench H. A simple method of estimating fifty percente endpoints. Am. J. Hyg. 1938;27:493–497.
  20. Paillot R, Prowse L, Montesso F, Huang CM, Barnes H, Escala J. Whole inactivated equine influenza vaccine: Efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity.. Vet Microbiol 2013 Mar 23;162(2-4):396-407.
    doi: 10.1016/j.vetmic.2012.10.019pubmed: 23146168google scholar: lookup
  21. Paillot R, Prowse L, Donald C, Medcalf E, Montesso F, Bryant N, Watson J, Jeggo M, Elton D, Newton R, Trail P, Barnes H. Efficacy of a whole inactivated EI vaccine against a recent EIV outbreak isolate and comparative detection of virus shedding.. Vet Immunol Immunopathol 2010 Aug 15;136(3-4):272-83.
    doi: 10.1016/j.vetimm.2010.03.019pubmed: 20400185google scholar: lookup
  22. OIE. Equine Influenza (Infection with Equine Influenza Virus): Chapter 2.5.7. .

Citations

This article has been cited 16 times.
  1. Whitlock F, Grewar J, Newton R. An epidemiological overview of the equine influenza epidemic in Great Britain during 2019. Equine Vet J 2023 Jan;55(1):153-164.
    doi: 10.1111/evj.13874pubmed: 36054725google scholar: lookup
  2. Nogales A, DeDiego ML, Martínez-Sobrido L. Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use. Front Cell Infect Microbiol 2022;12:954811.
    doi: 10.3389/fcimb.2022.954811pubmed: 35937688google scholar: lookup
  3. Pavulraj S, Bergmann T, Trombetta CM, Marchi S, Montomoli E, Alami SSE, Ragni-Alunni R, Osterrieder N, Azab W. Immunogenicity of Calvenza-03 EIV/EHV(®) Vaccine in Horses: Comparative In Vivo Study. Vaccines (Basel) 2021 Feb 17;9(2).
    doi: 10.3390/vaccines9020166pubmed: 33671378google scholar: lookup
  4. Reemers S, Sonnemans D, Horspool L, van Bommel S, Cao Q, van de Zande S. Determining Equine Influenza Virus Vaccine Efficacy-The Specific Contribution of Strain Versus Other Vaccine Attributes. Vaccines (Basel) 2020 Sep 3;8(3).
    doi: 10.3390/vaccines8030501pubmed: 32899189google scholar: lookup
  5. Fougerolle S, Fortier C, Legrand L, Jourdan M, Marcillaud-Pitel C, Pronost S, Paillot R. Success and Limitation of Equine Influenza Vaccination: The First Incursion in a Decade of a Florida Clade 1 Equine Influenza Virus that Shakes Protection Despite High Vaccine Coverage. Vaccines (Basel) 2019 Nov 2;7(4).
    doi: 10.3390/vaccines7040174pubmed: 31684097google scholar: lookup
  6. Blanco-Lobo P, Rodriguez L, Reedy S, Oladunni FS, Nogales A, Murcia PR, Chambers TM, Martinez-Sobrido L. A Bivalent Live-Attenuated Vaccine for the Prevention of Equine Influenza Virus. Viruses 2019 Oct 11;11(10).
    doi: 10.3390/v11100933pubmed: 31614538google scholar: lookup
  7. Dilai M, Piro M, El Harrak M, Fougerolle S, Dehhaoui M, Dikrallah A, Legrand L, Paillot R, Fassi Fihri O. Impact of Mixed Equine Influenza Vaccination on Correlate of Protection in Horses. Vaccines (Basel) 2018 Oct 4;6(4).
    doi: 10.3390/vaccines6040071pubmed: 30287762google scholar: lookup
  8. Singh RK, Dhama K, Karthik K, Khandia R, Munjal A, Khurana SK, Chakraborty S, Malik YS, Virmani N, Singh R, Tripathi BN, Munir M, van der Kolk JH. A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies. Front Microbiol 2018;9:1941.
    doi: 10.3389/fmicb.2018.01941pubmed: 30237788google scholar: lookup
  9. Paillot R, Garrett D, Lopez-Alvarez MR, Birand I, Montesso F, Horspool L. The Immunity Gap Challenge: Protection against a Recent Florida Clade 2 Equine Influenza Strain. Vaccines (Basel) 2018 Jul 2;6(3).
    doi: 10.3390/vaccines6030038pubmed: 30004410google scholar: lookup
  10. Gildea S, Garvey M, Lyons P, Lyons R, Gahan J, Walsh C, Cullinane A. Multifocal Equine Influenza Outbreak with Vaccination Breakdown in Thoroughbred Racehorses. Pathogens 2018 Apr 17;7(2).
    doi: 10.3390/pathogens7020043pubmed: 29673169google scholar: lookup
  11. Rodriguez L, Reedy S, Nogales A, Murcia PR, Chambers TM, Martinez-Sobrido L. Development of a novel equine influenza virus live-attenuated vaccine. Virology 2018 Mar;516:76-85.
    doi: 10.1016/j.virol.2018.01.005pubmed: 29331866google scholar: lookup
  12. Sreenivasan CC, Jandhyala SS, Luo S, Hause BM, Thomas M, Knudsen DEB, Leslie-Steen P, Clement T, Reedy SE, Chambers TM, Christopher-Hennings J, Nelson E, Wang D, Kaushik RS, Li F. Phylogenetic Analysis and Characterization of a Sporadic Isolate of Equine Influenza A H3N8 from an Unvaccinated Horse in 2015. Viruses 2018 Jan 11;10(1).
    doi: 10.3390/v10010031pubmed: 29324680google scholar: lookup
  13. Kleij L, Bruder E, Raoux-Barbot D, Lejal N, Nevers Q, Deloizy C, Da Costa B, Legrand L, Barrey E, Chenal A, Pronost S, Delmas B, Dhorne-Pollet S. Genomic characterization of equine influenza A subtype H3N8 viruses by long read sequencing and functional analyses of the PB1-F2 virulence factor of A/equine/Paris/1/2018. Vet Res 2024 Mar 22;55(1):36.
    doi: 10.1186/s13567-024-01289-8pubmed: 38520035google scholar: lookup
  14. Elliott S, Olufemi OT, Daly JM. Systematic Review of Equine Influenza A Virus Vaccine Studies and Meta-Analysis of Vaccine Efficacy. Viruses 2023 Nov 28;15(12).
    doi: 10.3390/v15122337pubmed: 38140577google scholar: lookup
  15. Ahmed BM, Bayoumi MM, Farrag MA, Elgamal MA, Daly JM, Amer HM. Emergence of equine influenza virus H3Nx Florida clade 2 in Arabian racehorses in Egypt. Virol J 2022 Nov 12;19(1):185.
    doi: 10.1186/s12985-022-01917-9pubmed: 36371185google scholar: lookup
  16. Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Kondo T, Matsumura T, Gildea S, Cullinane A. Assessment of antigenic difference of equine influenza virus strains by challenge study in horses. Influenza Other Respir Viruses 2016 Nov;10(6):536-539.
    doi: 10.1111/irv.12418pubmed: 27465864google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.